PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
55.90
-0.10 (-0.18%)
At close: Sep 25, 2025
330.00%
Market Cap 21.23B
Revenue (ttm) n/a
Net Income (ttm) -242.62M
Shares Out 385.96M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 454,000
Average Volume 456,709
Open 56.00
Previous Close 56.00
Day's Range 54.80 - 56.50
52-Week Range 8.68 - 57.70
Beta n/a
RSI 73.59
Earnings Date Aug 26, 2025

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the... [Read more]

Sector Materials
Founded 2008
Employees 53
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.